Adaptive Biotechnologies Corp — Director's Dealing 2020

May 13, 2020

SEC Form 4/A — Form 4/A

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2020-04-08

Reporting Person: Cohen Chad M (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-04-08	Common Stock	M	5000	$6.32	Acquired	6000	Direct
2020-04-08	Common Stock	M	10000	$4.07	Acquired	16000	Direct
2020-04-08	Common Stock	S	9700	$24.14	Disposed	6300	Direct
2020-04-08	Common Stock	S	5300	$25.07	Disposed	1000	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-04-08	Stock Option (Right to Buy)	$4.07	M	10000	Disposed	2025-03-31	Common Stock (10000)	Direct
2020-04-08	Stock Option (Right to Buy)	$6.32	M	5000	Disposed	2025-08-25	Common Stock (5000)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2019.

F2: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $23.78 to 24.71, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F3: The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $25.00 to 25.57, inclusive.

F4: The option is fully vested and exercisable.

F5: This transaction was omitted from the reporting person's original Form 4 due to an erroneous trade confirmation.